|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...7071727374757677787980...156157» |
- Turalio (pexidartinib) / Daiichi Sankyo
Enrollment change: Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate (clinicaltrials.gov) - Mar 17, 2015
P1, N=0, Withdrawn, Sponsor: Plexxikon
N=36 --> 0
- Tracleer (bosentan) / J&J, Roche
Clinical: TRADOMS: Transcranial Doppler in Multiple Sclerosis (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: Universitair Ziekenhuis Brussel
- Proleukin (aldesleukin) / Novartis, Prometheus, Iovance Biotherap
New P1/2 trial: ANEMIL: Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment (clinicaltrials.gov) - Mar 17, 2015
P1/2, N=10, Not yet recruiting, Sponsor: University Hospital, Bordeaux
- amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Enrollment open: Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients (clinicaltrials.gov) - Mar 17, 2015
P1, N=18, Recruiting, Sponsor: Mitsubishi Tanabe Pharma Corporation
N=36 --> 0 Not yet recruiting --> Recruiting
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed: TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Na (clinicaltrials.gov) - Mar 17, 2015
P3, N=57, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage (clinicaltrials.gov) - Mar 17, 2015
P4, N=429, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Completed --> Active, not recruiting
- | amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion: Comparative Oral Bioavailability Study of MT-1303 (clinicaltrials.gov) - Mar 17, 2015
P1, N=34, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Completed --> Active, not recruiting Recruiting --> Completed
- amiselimod (MT 1303) / Mitsubishi Tanabe, Bausch Health
Trial completion: Mass Balance Study of MT-1303 (clinicaltrials.gov) - Mar 17, 2015
P1, N=8, Completed, Sponsor: Mitsubishi Tanabe Pharma Corporation
Recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion: Impact of ELKa, the Toolset for Food Exchanges Calculation on Metabolic Control in Pediatric Diabetic Patients. (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=106, Completed, Sponsor: Medical University of Warsaw
Active, not recruiting --> Completed Recruiting --> Completed
- | DiabeCell (immunoprotected [alginate-encapsulated] porcine islets) / Living Cell Technologies
Trial completion: Open-label Investigation of the Safety and Efficacy of DIABECELL in Patients With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Mar 17, 2015
P2b, N=14, Completed, Sponsor: Living Cell Technologies
Recruiting --> Completed Active, not recruiting --> Completed
- | gimsilumab (KIN-1901) / Roivant, Eisai
Trial completion: MORAB022-001: Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects (clinicaltrials.gov) - Mar 17, 2015
P1, N=20, Completed, Sponsor: Morphotek
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Ilaris (canakinumab) / Novartis
Trial completion: ?-SPECIFIC 3: An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-na (clinicaltrials.gov) - Mar 17, 2015
P3, N=300, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- ||||| Calquence (acalabrutinib) / AstraZeneca
New P2 trial: ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate (clinicaltrials.gov) - Mar 14, 2015
P2, N=70, Not yet recruiting, Sponsor: Acerta Pharma BV
- andecaliximab (GS-5745) / Gilead
Enrollment closed, P1 data, PK/PD data: Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 14, 2015
P1, N=20, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Completed Recruiting --> Active, not recruiting
- || Trial primary completion date: Overnight Closed Loop Study in U.S. (clinicaltrials.gov) - Mar 14, 2015
P2, N=85, Recruiting, Sponsor: Medtronic Diabetes
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2014 --> Oct 2015
- Enrollment change, Trial termination, Trial primary completion date, IO biomarker: Defining Immune Tolerance in ANCA-associated Vasculitis (AAV) (clinicaltrials.gov) - Mar 14, 2015
P=N/A, N=34, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Oct 2014 --> Oct 2015 N=105 --> 34 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Mar 2015; Slow accrual
- || Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Enrollment closed: Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Mar 14, 2015
P1, N=105, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=105 --> 34 | Recruiting --> Terminated | Trial primary completion date: Sep 2016 --> Mar 2015; Slow accrual Recruiting --> Active, not recruiting
- || Trial primary completion date: The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=1000, Recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Aug 2015
- Avastin (bevacizumab) / Roche
Trial primary completion date: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - Mar 12, 2015
P1, N=10, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Jun 2016 --> Aug 2015 Trial primary completion date: Jan 2015 --> May 2015
- Enrollment change, IO biomarker: GENIAL: GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=140, Recruiting, Sponsor: Hospices Civils de Lyon
Trial primary completion date: Jan 2015 --> May 2015 N=60 --> 140
- ||| Tysabri (natalizumab) / Biogen, Royalty
HEOR: PROTYS: Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=88, Not yet recruiting, Sponsor: Biogen Idec
- | Trial completion: Accu-Chek Combo in Young Patients (clinicaltrials.gov) - Mar 12, 2015
P=N/A, N=13, Completed, Sponsor: Rabin Medical Center
N=60 --> 140 Active, not recruiting --> Completed
- |||| Promacta (eltrombopag) / Novartis
Trial completion, Trial primary completion date: A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Mar 12, 2015
P4, N=167, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> May 2014
- Trial primary completion date: RAFatigueRCT;FatigueRA-RCT: Fatigue in People With Rheumatoid Arthritis- Randomized Controlled Trial (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=70, Recruiting, Sponsor: Göteborg University
Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> May 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- Betaseron (IFN-β-1b) / Bayer
Trial withdrawal: Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) (clinicaltrials.gov) - Mar 10, 2015
P3, N=0, Withdrawn, Sponsor: Bayer
Trial primary completion date: Dec 2014 --> Dec 2015 Terminated --> Withdrawn
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed, Combination therapy, Monotherapy: A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Mar 10, 2015
P3, N=401, Active, not recruiting, Sponsor: Hoffmann-La Roche
Terminated --> Withdrawn Recruiting --> Active, not recruiting
- || Enrollment closed: Douleur-PR: Pain Evaluation in Rheumatoid Arthritis (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=300, Active, not recruiting, Sponsor: University Hospital, Limoges
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Epratucyn (epratuzumab) / Gilead
Trial completion: Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects (clinicaltrials.gov) - Mar 10, 2015
P2, N=17, Completed, Sponsor: UCB Pharma
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| glatiramer acetate / Generic mfg.
Trial completion: Efficacy and Safety of GTR in Comparison to Copaxone® (clinicaltrials.gov) - Mar 10, 2015
P3, N=750, Completed, Sponsor: Synthon BV
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change, Trial primary completion date: REUMAP: Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis (clinicaltrials.gov) - Mar 10, 2015
P2, N=6, Completed, Sponsor: Alloksys Life Sciences B.V.
Active, not recruiting --> Completed Recruiting --> Completed | N=10 --> 6 | Trial primary completion date: May 2012 --> Apr 2013
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka
New P2 trial: Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade (clinicaltrials.gov) - Mar 10, 2015
P2, N=20, Recruiting, Sponsor: ChemoCentryx
- Enrollment open, Trial initiation date, Trial primary completion date: Telecare in Type 1 Diabetes (T1D) Patients Treated by Insulin Pump (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=120, Recruiting, Sponsor: Assuta Hospital Systems
Recruiting --> Completed | N=10 --> 6 | Trial primary completion date: May 2012 --> Apr 2013 Not yet recruiting --> Recruiting | Initiation date: Jun 2013 --> Oct 2013 | Trial primary completion date: Dec 2014 --> Jan 2017
- ||||| Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment closed: An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - Mar 10, 2015
P3, N=52, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting | Initiation date: Jun 2013 --> Oct 2013 | Trial primary completion date: Dec 2014 --> Jan 2017 Recruiting --> Active, not recruiting
- Enrollment closed, Trial primary completion date: Assessment of an iPhone Application on Glycemic Control in Type 1 Diabetes (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=92, Active, not recruiting, Sponsor: The Hospital for Sick Children
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Mar 2016
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Enrollment change, Trial primary completion date: RITACT: A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 (clinicaltrials.gov) - Mar 10, 2015
P4, N=26, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2015 --> Mar 2016 Recruiting --> Active, not recruiting | N=82 --> 26 | Trial primary completion date: Mar 2016 --> Dec 2016
- Trial completion: SportGuard: Prevention of Hypoglycaemia With Predictive Insulin Suspend Using Sensor Augmented Insulin Pump in Children (clinicaltrials.gov) - Mar 10, 2015
P=N/A, N=100, Completed, Sponsor: University of Ljubljana, Faculty of Medicine
Recruiting --> Active, not recruiting | N=82 --> 26 | Trial primary completion date: Mar 2016 --> Dec 2016 Recruiting --> Completed
- |||| Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage (clinicaltrials.gov) - Mar 10, 2015
P4, N=429, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Recruiting --> Completed | N=618 --> 429 | Trial primary completion date: Sep 2016 --> Jan 2015
- | Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion, Combination therapy: Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes (clinicaltrials.gov) - Mar 10, 2015
P2, N=47, Completed, Sponsor: AstraZeneca
Recruiting --> Completed | N=618 --> 429 | Trial primary completion date: Sep 2016 --> Jan 2015 Active, not recruiting --> Completed
- Tysabri (natalizumab) / Biogen
Clinical: CogMS-Ext: Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension (clinicaltrials.gov) - Mar 9, 2015
P=N/A, N=47, Recruiting, Sponsor: Clinique Neuro-Outaouais
- || vatelizumab (GBR 500) / Glenmark
Enrollment status: Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 (clinicaltrials.gov) - Mar 9, 2015
P2, N=168, Enrolling by invitation, Sponsor: Genzyme, a Sanofi Company
Active, not recruiting --> Completed Recruiting --> Enrolling by invitation
- Clinical: CDiC: Changing Diabetes in Children (clinicaltrials.gov) - Mar 9, 2015
P=N/A, N=3089, Terminated, Sponsor: Novo Nordisk A/S
- Enrollment closed: A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes (clinicaltrials.gov) - Mar 9, 2015
P=N/A, N=675, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Enrolling by invitation Enrolling by invitation --> Active, not recruiting
- Enrollment closed, Enrollment change, Trial primary completion date: Functional MRI in Lupus Nephritis (clinicaltrials.gov) - Mar 9, 2015
P=N/A, N=50, Active, not recruiting, Sponsor: Biogen Idec
Enrolling by invitation --> Active, not recruiting Recruiting --> Active, not recruiting | N=80 --> 50 | Trial primary completion date: Dec 2014 --> Mar 2015
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed: Tocilizumab Treatment in Graves (clinicaltrials.gov) - Mar 9, 2015
P3, N=32, Active, not recruiting, Sponsor: Hospital Clinico Universitario de Santiago
Recruiting --> Active, not recruiting | N=80 --> 50 | Trial primary completion date: Dec 2014 --> Mar 2015 Recruiting --> Active, not recruiting
- Trial primary completion date, HEOR: PDMSLac: Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=39, Recruiting, Sponsor: Florida State University
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2014 --> Nov 2015
- Clinical: Evaluation of Non-surgical Periodontal Therapy in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=56, Completed, Sponsor: CAIO VINICIUS GONÇALVES ROMAN TORRES
- dalfampridine / Generic mfg.
Trial primary completion date: Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients (clinicaltrials.gov) - Mar 7, 2015
P4, N=50, Recruiting, Sponsor: Clinique Neuro-Outaouais
Trial primary completion date: Nov 2014 --> Nov 2015 Trial primary completion date: Dec 2014 --> Jul 2015
- |||| Ilaris (canakinumab) / Novartis
Trial primary completion date: An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (clinicaltrials.gov) - Mar 7, 2015
P3, N=220, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Jul 2015 Trial primary completion date: Sep 2014 --> Apr 2015
- Diamyd (rhGAD65/alum) / Diamyd Medical
Trial primary completion date: DIAPREV-IT: Diabetes Prevention - Immune Tolerance (clinicaltrials.gov) - Mar 7, 2015
P2, N=50, Active, not recruiting, Sponsor: Lund University
Trial primary completion date: Sep 2014 --> Apr 2015 Trial primary completion date: Jan 2015 --> Dec 2016
- | dexamethasone / Generic mfg.
Enrollment change: Caffeic Acid Tablets as a Second-line Therapy for ITP (clinicaltrials.gov) - Mar 7, 2015
P3, N=120, Recruiting, Sponsor: Shandong University
Trial primary completion date: Jan 2015 --> Dec 2016 N=200 --> 120